Spruce Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 29
- Market Cap
- $19.7M
- Website
- http://www.sprucebio.com
Clinical Trials
25
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Spruce Biosciences
- Target Recruit Count
- 27
- Registration Number
- NCT05370521
- Locations
- 🇺🇸
Spruce Study Site, Morgantown, West Virginia, United States
A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children with CAH
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Spruce Biosciences
- Target Recruit Count
- 65
- Registration Number
- NCT05128942
- Locations
- 🇺🇸
Spruce Study Site, Richmond, Virginia, United States
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH
- Conditions
- Congenital Adrenal Hyperplasia
- Interventions
- Drug: Tildacerfont/Placebo
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Spruce Biosciences
- Target Recruit Count
- 100
- Registration Number
- NCT04544410
- Locations
- 🇬🇧
Spruce Study Site, Birmingham, United Kingdom
🇺🇸Spruce Biosciences Clinical Site, Ann Arbor, Michigan, United States
A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH
- Conditions
- Congenital Adrenal Hyperplasia
- Interventions
- Drug: Tildacerfont/Placebo
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Spruce Biosciences
- Target Recruit Count
- 96
- Registration Number
- NCT04457336
- Locations
- 🇬🇧
Spruce Study Site, Birmingham, United Kingdom
🇺🇸Spruce Clinical Site, Fort Worth, Texas, United States
🇦🇺Spruce study site, Brisbane, Australia
Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
- Conditions
- CAH - Congenital Adrenal HyperplasiaCAH - 21-Hydroxylase DeficiencyCongenital Adrenal Hyperplasia
- Interventions
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Spruce Biosciences
- Target Recruit Count
- 11
- Registration Number
- NCT03687242
- Locations
- 🇺🇸
Spruce Biosciences Clinical Site, Philadelphia, Pennsylvania, United States
- Prev
- 1
- 2
- Next
News
Spruce Biosciences Acquires Tralesinidase Alfa for Sanfilippo Syndrome Type B Treatment with BLA Submission Planned for 2026
Spruce Biosciences has acquired tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B, a neurodegenerative and fatal genetic disease with no FDA-approved treatments.
FDA Grants Priority Review to Crinecerfont for Congenital Adrenal Hyperplasia
• The FDA has accepted two New Drug Applications for Neurocrine Biosciences' crinecerfont, granting Priority Review for treating classic congenital adrenal hyperplasia (CAH). • Crinecerfont, a selective CRF1 receptor antagonist, aims to manage ACTH and androgen levels without glucocorticoids, potentially revolutionizing CAH treatment. • If approved, crinecerfont would be the first new CAH treatment in 70 years, offering a novel mechanism to address this rare endocrine disorder. • The CAH market is expected to grow significantly, driven by emerging therapies like crinecerfont, with a projected CAGR of ~40% to reach USD 20 billion by 2034.